CD47 blockade reverses resistance to HDAC inhibitor by liberating anti-tumor capacity of macrophages.

ABSTRACT:

Background

Targeting oncogenic histone modification by histone deacetylase inhibitors (HDACis) demonstrates promising prospects in clinical cancer treatment, whereas a notable proportion of patients cannot benefit from HDACi therapy. This study aims to explore how HDACi influences the tumor microenvironment, in order to identify potential targets for reversing the resistance to HDACi therapies.

Methods

Macrophage infiltration was compared between HDACi-responding and HDACi-nonresponding cancer patients. The impact of HDACis on the phagocytic capacity of macrophages was investigated through macrophage-tumor cell co-culture system. CD47 expression in tumor cell lines and patient-derived organoids was evaluated by quantitative polymerase chain reaction (QPCR) and flow cytometry

SUBMITTER: Xu X 

PROVIDER: S-EPMC11849317 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature